tiprankstipranks
Trending News
More News >

Prothena price target lowered to $14 from $30 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $14 from $30 and keeps a Buy rating on the shares after the company announced that the AFFIRM-AL trial did not show statistical significance on the survival benefit, the primary endpoint for the study. The firm removed birtamimab from the current valuation but says PRX012 remains on track.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue